Castro Maria

Title(s)Professor, Medicine
Phone(310) 423-7303
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Immune-mediated therapies in a genetically engineered murine model of diffuse intrinsic pontine glioma
    NIH/NINDS R21NS107894Apr 1, 2019 - Mar 31, 2021
    Role: Principal Investigator
    Interactions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas: implications for therapeutics
    NIH/NINDS R01NS105556Apr 1, 2018 - Feb 28, 2023
    Role: Principal Investigator
    Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies
    NIH/NINDS R01NS094804Sep 1, 2015 - Jun 30, 2020
    Role: Principal Investigator
    Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies
    NIH/NINDS R37NS094804Sep 1, 2015 - Jun 30, 2019
    Role: Principal Investigator
    HDL-Loaded Nanoparticles for Glioma Therapeutics
    NIH/NINDS R21NS091555Feb 1, 2015 - Jan 31, 2017
    Role: Principal Investigator
    Crosstalk between glioma cells &immune cells in the tumor microenvironment: Ther
    NIH/NINDS R01NS074387Apr 5, 2011 - Feb 29, 2016
    Role: Principal Investigator
    Engineering the Brain Immune System for Tumor Therapy
    NIH/NINDS R01NS057711Jan 15, 2009 - Dec 31, 2014
    Role: Principal Investigator
    Gutless Adenovirus Mediated Gene Therapy for Glioma
    NIH/NINDS U01NS052465Sep 19, 2007 - Aug 31, 2014
    Role: Principal Investigator
    Targeted Toxin for Brain Cancer Gene Therapy
    NIH/NINDS R21NS054143Feb 1, 2007 - Jan 31, 2010
    Role: Principal Investigator
    NIH/FIC R03TW006273Mar 1, 2004 - Feb 28, 2007
    Role: Principal Investigator
    Gene therapy for chronic neurodegenerative disorders
    NIH/NINDS R01NS044556Aug 1, 2002 - Jul 31, 2008
    Role: Principal Investigator
    Cancer Biology Training Program
    NIH/NCI T32CA009676Sep 1, 1992 - Aug 31, 2023
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Oliver CR, Altemus MA, Westerhof TM, Cheriyan H, Cheng X, Dziubinski M, Wu Z, Yates J, Morikawa A, Heth J, Castro MG, Leung BM, Takayama S, Merajver SD. A platform for artificial intelligence based identification of the extravasation potential of cancer cells into the brain metastatic niche. Lab Chip. 2019 Feb 27. PMID: 30810557.
      View in: PubMed
    2. Núñez FJ, Mendez FM, Kadiyala P, Alghamri MS, Savelieff MG, Garcia-Fabiani MB, Haase S, Koschmann C, Calinescu AA, Kamran N, Saxena M, Patel R, Carney S, Guo MZ, Edwards M, Ljungman M, Qin T, Sartor MA, Tagett R, Venneti S, Brosnan-Cashman J, Meeker A, Gorbunova V, Zhao L, Kremer DM, Zhang L, Lyssiotis CA, Jones L, Herting CJ, Ross JL, Hambardzumyan D, Hervey-Jumper S, Figueroa ME, Lowenstein PR, Castro MG. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Sci Transl Med. 2019 Feb 13; 11(479). PMID: 30760578.
      View in: PubMed
    3. Kadiyala P, Li D, Nuñez FM, Altshuler D, Doherty R, Kuai R, Yu M, Kamran N, Edwards M, Moon JJ, Lowenstein PR, Castro MG, Schwendeman A. High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme. ACS Nano. 2019 Feb 11. PMID: 30721028.
      View in: PubMed
    4. Núñez FJ, Mendez FM, Garcia-Fabiani MB, Pardo J, Edwards M, Lowenstein PR, Castro MG. Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures. J Vis Exp. 2019 Jan 09; (143). PMID: 30688315.
      View in: PubMed
    5. Yadav VN, Altshuler D, Kadiyala P, Zamler D, Comba A, Appelman H, Dunn P, Koschmann C, Castro MG, Löwenstein PR. Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab. Neuro Oncol. 2018 Sep 03; 20(10):1356-1367. PMID: 29660022.
      View in: PubMed
    6. Haase S, Garcia-Fabiani MB, Carney S, Altshuler D, Núñez FJ, Méndez FM, Núñez F, Lowenstein PR, Castro MG. Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opin Ther Targets. 2018 Jul; 22(7):599-613. PMID: 29889582.
      View in: PubMed
    7. Kamran N, Alghamri MS, Nunez FJ, Shah D, Asad AS, Candolfi M, Altshuler D, Lowenstein PR, Castro MG. Current state and future prospects of immunotherapy for glioma. Immunotherapy. 2018 Feb 01; 10(4):317-339. PMID: 29421984.
      View in: PubMed
    8. Mendez FM, Núñez FJ, Zorrilla-Veloz RI, Lowenstein PR, Castro MG. Native Chromatin Immunoprecipitation Using Murine Brain Tumor Neurospheres. J Vis Exp. 2018 01 29; (131). PMID: 29443090.
      View in: PubMed
    9. Kamran N, Li Y, Sierra M, Alghamri MS, Kadiyala P, Appelman HD, Edwards M, Lowenstein PR, Castro MG. Melanoma induced immunosuppression is mediated by hematopoietic dysregulation. Oncoimmunology. 2018; 7(3):e1408750. PMID: 29399415.
      View in: PubMed
    10. Koschmann C, Farooqui Z, Kasaian K, Cao X, Zamler D, Stallard S, Venneti S, Hervey-Jumper S, Garton H, Muraszko K, Franchi L, Robertson PL, Leonard M, Opipari V, Castro MG, Lowenstein PR, Chinnaiyan A, Mody R. Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event. NPJ Precis Oncol. 2017; 1(1):32. PMID: 29872713.
      View in: PubMed
    11. Lowenstein PR, Castro MG. Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. Clin Immunol. 2018 Apr; 189:43-51. PMID: 28720549.
      View in: PubMed
    12. Moreno Ayala MA, Gottardo MF, Gori MS, Nicola Candia AJ, Caruso C, De Laurentiis A, Imsen M, Klein S, Bal de Kier Joffé E, Salamone G, Castro MG, Seilicovich A, Candolfi M. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer. J Cancer Res Clin Oncol. 2017 Sep; 143(9):1713-1732. PMID: 28432455.
      View in: PubMed
    13. Chandran M, Candolfi M, Shah D, Mineharu Y, Yadav VN, Koschmann C, Asad AS, Lowenstein PR, Castro MG. Single vs. combination immunotherapeutic strategies for glioma. Expert Opin Biol Ther. 2017 05; 17(5):543-554. PMID: 28286975.
      View in: PubMed
    14. Ashley SL, Pretto CD, Stier MT, Kadiyala P, Castro-Jorge L, Hsu TH, Doherty R, Carnahan KE, Castro MG, Lowenstein PR, Spindler KR. Matrix Metalloproteinase Activity in Infections by an Encephalitic Virus, Mouse Adenovirus Type 1. J Virol. 2017 03 15; 91(6). PMID: 28053109.
      View in: PubMed
    15. Koschmann C, Nunez FJ, Mendez F, Brosnan-Cashman JA, Meeker AK, Lowenstein PR, Castro MG. Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer. Cancer Res. 2017 01 15; 77(2):227-233. PMID: 28062403.
      View in: PubMed
    16. Kamran N, Kadiyala P, Saxena M, Candolfi M, Li Y, Moreno-Ayala MA, Raja N, Shah D, Lowenstein PR, Castro MG. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. Mol Ther. 2017 01 04; 25(1):232-248. PMID: 28129117.
      View in: PubMed
    17. Yadav VN, Zamler D, Baker GJ, Kadiyala P, Erdreich-Epstein A, DeCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study. Oncotarget. 2016 12 13; 7(50):83701-83719. PMID: 27863376.
      View in: PubMed
    18. King GD, Kroeger KM, Bresee CJ, Candolfi M, Liu C, Manalo CM, Muhammad AG, Pechnick RN, Lowenstein PR, Castro MG. Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor-induced Behavioral Deficits. Mol Ther. 2008 Apr; 16(4):682-690. PMID: 28178463.
      View in: PubMed
    19. Kamran N, Chandran M, Lowenstein PR, Castro MG. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. Clin Immunol. 2018 Apr; 189:34-42. PMID: 27777083.
      View in: PubMed
    20. Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D, Peterson L, Camelo-Piragua S, Jones C, Mody R, Lowenstein PR, Castro MG. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget. 2016 Oct 04; 7(40):65696-65706. PMID: 27582545.
      View in: PubMed
    21. Wilson TJ, Zamler DB, Doherty R, Castro MG, Lowenstein PR. Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery tool. Oncotarget. 2016 09 27; 7(39):63020-63041. PMID: 27564115.
      View in: PubMed
    22. Lowenstein PR, Castro MG. Multiple Expressed Endogenous Glioma Epitopes as Novel Vaccines for Gliomas. Clin Cancer Res. 2016 Oct 01; 22(19):4760-4762. PMID: 27521444.
      View in: PubMed
    23. Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad AS, Koschmann C, Nunez FJ, Lowenstein PR, Castro MG. Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther. 2016 10; 16(10):1245-64. PMID: 27411023.
      View in: PubMed
    24. Calinescu AA, Castro MG. Microtubule targeting agents in glioma. Transl Cancer Res. 2016 Jun; 5(Suppl 1):S54-S60. PMID: 30680290.
      View in: PubMed
    25. VanderVeen N, Raja N, Yi E, Appelman H, Ng P, Palmer D, Zamler D, Dzaman M, Lowenstein PR, Castro MG. Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model. Hum Gene Ther Methods. 2016 06; 27(3):98-111. PMID: 27056322.
      View in: PubMed
    26. Koschmann C, Lowenstein PR, Castro MG. ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability. Mol Cell Oncol. 2016 May; 3(3):e1167158. PMID: 27314101.
      View in: PubMed
    27. Baker GJ, Chockley P, Zamler D, Castro MG, Lowenstein PR. Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells. Oncoimmunology. 2016 Jun; 5(6):e1163461. PMID: 27471637.
      View in: PubMed
    28. Koschmann C, Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, Mendez F, Kamran N, Dzaman M, Mulpuri L, Krasinkiewicz J, Doherty R, Lemons R, Brosnan-Cashman JA, Li Y, Roh S, Zhao L, Appelman H, Ferguson D, Gorbunova V, Meeker A, Jones C, Lowenstein PR, Castro MG. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci Transl Med. 2016 Mar 02; 8(328):328ra28. PMID: 26936505.
      View in: PubMed
    29. Kamran N, Candolfi M, Baker GJ, Ayala MM, Dzaman M, Lowenstein PR, Castro MG. Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. Methods Mol Biol. 2016; 1382:467-82. PMID: 26611605.
      View in: PubMed
    30. Baker GJ, Castro MG, Lowenstein PR. Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells. J Vis Exp. 2015 Nov 28; (105). PMID: 26650233.
      View in: PubMed
    31. Calinescu AA, Núñez FJ, Koschmann C, Kolb BL, Lowenstein PR, Castro MG. Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma. J Vis Exp. 2015 Feb 22; (96). PMID: 25741859; PMCID: PMC4354658.
    32. Lowenstein PR, Baker GJ, Castro MG. Cracking the glioma-NK inhibitory code: toward successful innate immunotherapy. Oncoimmunology. 2014 Nov; 3(11):e965573. PMID: 25941594.
      View in: PubMed
    33. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fucíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014 Oct; 3(9):e955691. PMID: 25941621.
      View in: PubMed
    34. Lowenstein PR, Castro MG. Glioma trials and viral tribulations: can anything be concluded from non-controlled trials? J Neurol Neurosurg Psychiatry. 2015 Feb; 86(2):125. PMID: 25280917; PMCID: PMC4677476.
    35. Mineharu Y, Kamran N, Lowenstein PR, Castro MG. Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. Mol Cancer Ther. 2014 Dec; 13(12):3024-36. PMID: 25256739; PMCID: PMC4258521.
    36. Baker GJ, Chockley P, Yadav VN, Doherty R, Ritt M, Sivaramakrishnan S, Castro MG, Lowenstein PR. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res. 2014 Sep 15; 74(18):5079-90. PMID: 25038230; PMCID: PMC4184887.
    37. Lynes J, Wibowo M, Koschmann C, Baker GJ, Saxena V, Muhammad AK, Bondale N, Klein J, Assi H, Lieberman AP, Castro MG, Lowenstein PR. Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H. Neurotherapeutics. 2014 Jul; 11(3):623-35. PMID: 24752661; PMCID: PMC4121445.
    38. Baker GJ, Yadav VN, Motsch S, Koschmann C, Calinescu AA, Mineharu Y, Camelo-Piragua SI, Orringer D, Bannykh S, Nichols WS, deCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia. 2014 Jul; 16(7):543-61. PMID: 25117977; PMCID: PMC4198934.
    39. Castro MG, Baker GJ, Lowenstein PR. Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier! Clin Cancer Res. 2014 Oct 15; 20(20):5147-9. PMID: 24879798; PMCID: PMC4330468.
    40. Assi H, Espinosa J, Suprise S, Sofroniew M, Doherty R, Zamler D, Lowenstein PR, Castro MG. Assessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBM. PLoS One. 2014; 9(5):e96318. PMID: 24806510; PMCID: PMC4013007.
    41. Castro MG, Candolfi M, Wilson TJ, Calinescu A, Paran C, Kamran N, Koschmann C, Moreno-Ayala MA, Assi H, Lowenstein PR. Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther. 2014 Sep; 14(9):1241-57. PMID: 24773178; PMCID: PMC4127140.
    42. Assi HH, Paran C, VanderVeen N, Savakus J, Doherty R, Petruzzella E, Hoeschele JD, Appelman H, Raptis L, Mikkelsen T, Lowenstein PR, Castro MG. Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy. J Pharmacol Exp Ther. 2014 Jun; 349(3):458-69. PMID: 24696041; PMCID: PMC4019317.
    43. Candolfi M, Yagiz K, Wibowo M, Ahlzadeh GE, Puntel M, Ghiasi H, Kamran N, Paran C, Lowenstein PR, Castro MG. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clin Cancer Res. 2014 Mar 15; 20(6):1555-1565. PMID: 24501391; PMCID: PMC3959570.
    44. VanderVeen N, Paran C, Appelhans A, Krasinkiewicz J, Lemons R, Appelman H, Doherty R, Palmer D, Ng P, Lowenstein PR, Castro MG. Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. Mol Ther Methods Clin Dev. 2014 Feb 05; 1. PMID: 25068145.
      View in: PubMed
    45. Lowenstein PR, Castro MG. The value of EGFRvIII as the target for glioma vaccines. Am Soc Clin Oncol Educ Book. 2014; 42-50. PMID: 24857059.
      View in: PubMed
    46. Mineharu Y, Castro MG, Lowenstein PR, Sakai N, Miyamoto S. Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. Neurol Med Chir (Tokyo). 2013; 53(11):741-54. PMID: 24140772; PMCID: PMC3926207.
    47. Castro MG, Lowenstein PR. Neuro-oncology: The long and winding road--gene therapy for glioma. Nat Rev Neurol. 2013 Nov; 9(11):609-10. PMID: 24061435; PMCID: PMC3928109.
    48. VanderVeen N, Paran C, Krasinkiewicz J, Zhao L, Palmer D, Hervey-Jumper S, Ng P, Lowenstein PR, Castro MG. Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma. Hum Gene Ther Clin Dev. 2013 Sep; 24(3):116-26. PMID: 24007469; PMCID: PMC4003468.
    49. Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ, Wolfe JH, Glorioso JC. Progress in gene therapy for neurological disorders. Nat Rev Neurol. 2013 May; 9(5):277-91. PMID: 23609618; PMCID: PMC3908892.
    50. Puntel M, A K M GM, Farrokhi C, Vanderveen N, Paran C, Appelhans A, Kroeger KM, Salem A, Lacayo L, Pechnick RN, Kelson KR, Kaur S, Kennedy S, Palmer D, Ng P, Liu C, Krasinkiewicz J, Lowenstein PR, Castro MG. Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. Toxicol Appl Pharmacol. 2013 May 01; 268(3):318-30. PMID: 23403069; PMCID: PMC3641940.
    51. Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-?B signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics. 2012 Oct; 9(4):827-43. PMID: 22996231; PMCID: PMC3480576.
    52. Muhammad AK, Xiong W, Puntel M, Farrokhi C, Kroeger KM, Salem A, Lacayo L, Pechnick RN, Kelson KR, Palmer D, Ng P, Liu C, Lowenstein PR, Castro MG. Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial. Hum Gene Ther Methods. 2012 Aug; 23(4):271-84. PMID: 22950971.
      View in: PubMed
    53. Assi H, Candolfi M, Baker G, Mineharu Y, Lowenstein PR, Castro MG. Gene therapy for brain tumors: basic developments and clinical implementation. Neurosci Lett. 2012 Oct 11; 527(2):71-7. PMID: 22906921; PMCID: PMC3462660.
    54. Candolfi M, King GD, Yagiz K, Curtin JF, Mineharu Y, Muhammad AK, Foulad D, Kroeger KM, Barnett N, Josien R, Lowenstein PR, Castro MG. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. Neoplasia. 2012 Aug; 14(8):757-70. PMID: 22952428; PMCID: PMC3431182.
    55. Sanderson NS, Puntel M, Kroeger KM, Bondale NS, Swerdlow M, Iranmanesh N, Yagita H, Ibrahim A, Castro MG, Lowenstein PR. Cytotoxic immunological synapses do not restrict the action of interferon-? to antigenic target cells. Proc Natl Acad Sci U S A. 2012 May 15; 109(20):7835-40. PMID: 22547816; PMCID: PMC3356634.
    56. Lowenstein PR, Castro MG. Pushing the limits of glioma resection using electrophysiologic brain mapping. J Clin Oncol. 2012 Jul 10; 30(20):2437-40. PMID: 22529267.
      View in: PubMed
    57. Zirger JM, Puntel M, Bergeron J, Wibowo M, Moridzadeh R, Bondale N, Barcia C, Kroeger KM, Liu C, Castro MG, Lowenstein PR. Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFN?, perforin, and TNFa, and due to the elimination of transduced cells. Mol Ther. 2012 Apr; 20(4):808-19. PMID: 22233583.
      View in: PubMed
    58. Candolfi M, Kroeger KM, Xiong W, Liu C, Puntel M, Yagiz K, Muhammad AG, Mineharu Y, Foulad D, Wibowo M, Assi H, Baker GJ, Lowenstein PR, Castro MG. Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. Anticancer Agents Med Chem. 2011 Oct; 11(8):729-38. PMID: 21707497; PMCID: PMC3364590.
    59. Candolfi M, Curtin JF, Yagiz K, Assi H, Wibowo MK, Alzadeh GE, Foulad D, Muhammad AK, Salehi S, Keech N, Puntel M, Liu C, Sanderson NR, Kroeger KM, Dunn R, Martins G, Lowenstein PR, Castro MG. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia. 2011 Oct; 13(10):947-60. PMID: 22028620; PMCID: PMC3201571.
    60. Puntel M, Barrett R, Sanderson NS, Kroeger KM, Bondale N, Wibowo M, Kennedy S, Liu C, Castro MG, Lowenstein PR. Identification and visualization of CD8+ T cell mediated IFN-? signaling in target cells during an antiviral immune response in the brain. PLoS One. 2011; 6(8):e23523. PMID: 21897844; PMCID: PMC3163574.
    61. Mineharu Y, King GD, Muhammad AK, Bannykh S, Kroeger KM, Liu C, Lowenstein PR, Castro MG. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin Cancer Res. 2011 Jul 15; 17(14):4705-18. PMID: 21632862; PMCID: PMC3208508.
    62. Castro MG, Candolfi M, Kroeger K, King GD, Curtin JF, Yagiz K, Mineharu Y, Assi H, Wibowo M, Ghulam Muhammad AK, Foulad D, Puntel M, Lowenstein PR. Gene therapy and targeted toxins for glioma. Curr Gene Ther. 2011 Jun; 11(3):155-80. PMID: 21453286.
      View in: PubMed
    63. King GD, Muhammad AK, Larocque D, Kelson KR, Xiong W, Liu C, Sanderson NS, Kroeger KM, Castro MG, Lowenstein PR. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther. 2011 Oct; 19(10):1793-801. PMID: 21505426; PMCID: PMC3188756.
    64. Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, Rodriguez R, Lowenstein PR, Castro MG. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A. 2010 Nov 16; 107(46):20021-6. PMID: 21030678; PMCID: PMC2993419.
    65. Kroeger KM, Muhammad AK, Baker GJ, Assi H, Wibowo MK, Xiong W, Yagiz K, Candolfi M, Lowenstein PR, Castro MG. Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med. 2010 Oct; 10(53):293-304. PMID: 21034670; PMCID: PMC3059086.
    66. Larocque D, Sanderson NS, Bergeron J, Curtin JF, Girton J, Wibowo M, Bondale N, Kroeger KM, Yang J, Lacayo LM, Reyes KC, Farrokhi C, Pechnick RN, Castro MG, Lowenstein PR. Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology. Proc Natl Acad Sci U S A. 2010 Aug 10; 107(32):14443-8. PMID: 20660723; PMCID: PMC2922551.
    67. Xiong W, Candolfi M, Liu C, Muhammad AK, Yagiz K, Puntel M, Moore PF, Avalos J, Young JD, Khan D, Donelson R, Pluhar GE, Ohlfest JR, Wawrowsky K, Lowenstein PR, Castro MG. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. PLoS One. 2010 Jun 11; 5(6):e11074. PMID: 20552015; PMCID: PMC2884015.
    68. Puntel M, Muhammad AK, Candolfi M, Salem A, Yagiz K, Farrokhi C, Kroeger KM, Xiong W, Curtin JF, Liu C, Bondale NS, Lerner J, Pechnick RN, Palmer D, Ng P, Lowenstein PR, Castro MG. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. J Virol. 2010 Jun; 84(12):6007-17. PMID: 20375153; PMCID: PMC2876634.
    69. Pluhar GE, Grogan PT, Seiler C, Goulart M, Santacruz KS, Carlson C, Chen W, Olin MR, Lowenstein PR, Castro MG, Haines SJ, Ohlfest JR. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine. 2010 Apr 26; 28(19):3371-8. PMID: 20197146; PMCID: PMC2854671.
    70. Puntel M, Kroeger KM, Sanderson NS, Thomas CE, Castro MG, Lowenstein PR. Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci. 2010 Jan; Chapter 4:Unit 4.24. PMID: 20066657; PMCID: PMC2883311.
    71. Saghizadeh M, Kramerov AA, Yu FS, Castro MG, Ljubimov AV. Normalization of wound healing and diabetic markers in organ cultured human diabetic corneas by adenoviral delivery of c-Met gene. Invest Ophthalmol Vis Sci. 2010 Apr; 51(4):1970-80. PMID: 19933191; PMCID: PMC2846188.
    72. Saghizadeh M, Kramerov AA, Yaghoobzadeh Y, Hu J, Ljubimova JY, Black KL, Castro MG, Ljubimov AV. Adenovirus-driven overexpression of proteinases in organ-cultured normal human corneas leads to diabetic-like changes. Brain Res Bull. 2010 Feb 15; 81(2-3):262-72. PMID: 19828126; PMCID: PMC2815249.
    73. Lowenstein PR, Castro MG. Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther. 2009 Oct; 9(5):368-74. PMID: 19860651.
      View in: PubMed
    74. Castro MG, Lowenstein PR. Gene therapy continues to make progress: clinical and regulatory perspectives. Curr Gene Ther. 2009 Oct; 9(5):327-8. PMID: 19860647.
      View in: PubMed
    75. Lowenstein PR, Lowenstein ED, Castro MG. Challenges in the evaluation, consent, ethics and history of early clinical trials - Implications of the Tuskegee 'trial' for safer and more ethical clinical trials. Curr Opin Mol Ther. 2009 Oct; 11(5):481-4. PMID: 19806495; PMCID: PMC2864135.
    76. Candolfi M, Kroeger KM, Muhammad AK, Yagiz K, Farrokhi C, Pechnick RN, Lowenstein PR, Castro MG. Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther. 2009 Oct; 9(5):409-21. PMID: 19860655.
      View in: PubMed
    77. Ghulam Muhammad AK, Candolfi M, King GD, Yagiz K, Foulad D, Mineharu Y, Kroeger KM, Treuer KA, Nichols WS, Sanderson NS, Yang J, Khayznikov M, Van Rooijen N, Lowenstein PR, Castro MG. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res. 2009 Oct 01; 15(19):6113-27. PMID: 19789315; PMCID: PMC2796687.
    78. Barcia C, Gómez A, Gallego-Sanchez JM, Perez-Vallés A, Castro MG, Lowenstein PR, Barcia C, Herrero MT. Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells. Am J Pathol. 2009 Aug; 175(2):786-98. PMID: 19628762; PMCID: PMC2716973.
    79. Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, Muhammad AK, Puntel M, Kroeger KM, Liu C, Lee S, Curtin JF, King GD, Lerner J, Sato K, Mineharu Y, Xiong W, Lowenstein PR, Castro MG. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res. 2009 Jul 01; 15(13):4401-14. PMID: 19570774; PMCID: PMC2769255.
    80. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, Muhammad AK, Clark MC, Arditi M, Comin-Anduix B, Ribas A, Lowenstein PR, Castro MG. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009 Jan 13; 6(1):e10. PMID: 19143470; PMCID: PMC2621261.
    81. Southgate T, Kroeger KM, Liu C, Lowenstein PR, Castro MG. Gene transfer into neural cells in vitro using adenoviral vectors. Curr Protoc Neurosci. 2008 Oct; Chapter 4:Unit 4.23. PMID: 18972378; PMCID: PMC2659706.
    82. Barcia C, Sanderson NS, Barrett RJ, Wawrowsky K, Kroeger KM, Puntel M, Liu C, Castro MG, Lowenstein PR. T cells' immunological synapses induce polarization of brain astrocytes in vivo and in vitro: a novel astrocyte response mechanism to cellular injury. PLoS One. 2008 Aug 20; 3(8):e2977. PMID: 18714338; PMCID: PMC2496894.
    83. Barcia C, Gomez A, de Pablos V, Fernández-Villalba E, Liu C, Kroeger KM, Martín J, Barreiro AF, Castro MG, Lowenstein PR, Herrero MT. CD20, CD3, and CD40 ligand microclusters segregate three-dimensionally in vivo at B-cell-T-cell immunological synapses after viral immunity in primate brain. J Virol. 2008 Oct; 82(20):9978-93. PMID: 18684835; PMCID: PMC2566292.
    84. Curtin JF, Candolfi M, Fakhouri TM, Liu C, Alden A, Edwards M, Lowenstein PR, Castro MG. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One. 2008 Apr 23; 3(4):e1983. PMID: 18431473; PMCID: PMC2291560.
    85. Curtin JF, Candolfi M, Xiong W, Lowenstein PR, Castro MG. Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Mol Cancer Ther. 2008 Mar; 7(3):439-48. PMID: 18347132; PMCID: PMC2593107.
    86. King GD, Muhammad AK, Xiong W, Kroeger KM, Puntel M, Larocque D, Palmer D, Ng P, Lowenstein PR, Castro MG. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. J Virol. 2008 May; 82(9):4680-4. PMID: 18287240; PMCID: PMC2293067.
    87. King GD, Kroeger KM, Bresee CJ, Candolfi M, Liu C, Manalo CM, Muhammad AK, Pechnick RN, Lowenstein PR, Castro MG. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol Ther. 2008 Apr; 16(4):682-90. PMID: 18283279; PMCID: PMC2593113.
    88. Barcia C, Wawrowsky K, Barrett RJ, Liu C, Castro MG, Lowenstein PR. In vivo polarization of IFN-gamma at Kupfer and non-Kupfer immunological synapses during the clearance of virally infected brain cells. J Immunol. 2008 Feb 01; 180(3):1344-52. PMID: 18209028; PMCID: PMC2629497.
    89. Xiong W, Candolfi M, Kroeger KM, Puntel M, Mondkar S, Larocque D, Liu C, Curtin JF, Palmer D, Ng P, Lowenstein PR, Castro MG. Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol Ther. 2008 Feb; 16(2):343-51. PMID: 18180781; PMCID: PMC2703652.
    90. Curtin JF, Candolfi M, Puntel M, Xiong W, Muhammad AK, Kroeger K, Mondkar S, Liu C, Bondale N, Lowenstein PR, Castro MG. Regulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators. Methods Mol Biol. 2008; 434:239-66. PMID: 18470649; PMCID: PMC2633597.
    91. King GD, Muhammad AK, Curtin JF, Barcia C, Puntel M, Liu C, Honig SB, Candolfi M, Mondkar S, Lowenstein PR, Castro MG. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol. 2008 Feb; 10(1):19-31. PMID: 18079358; PMCID: PMC2600834.
    92. Lowenstein PR, Kroeger K, Castro MG. Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses. Neurotherapeutics. 2007 Oct; 4(4):715-24. PMID: 17920552; PMCID: PMC2268648.
    93. Lowenstein PR, Mandel RJ, Xiong WD, Kroeger K, Castro MG. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther. 2007 Oct; 7(5):347-60. PMID: 17979681.
      View in: PubMed
    94. Barcia C, Jimenez-Dalmaroni M, Kroeger KM, Puntel M, Rapaport AJ, Larocque D, King GD, Johnson SA, Liu C, Xiong W, Candolfi M, Mondkar S, Ng P, Palmer D, Castro MG, Lowenstein PR. One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications. Mol Ther. 2007 Dec; 15(12):2154-63. PMID: 17895861; PMCID: PMC2268647.
    95. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, Moore PF, Lerner J, Lowenstein PR, Castro MG. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol. 2007 Nov; 85(2):133-48. PMID: 17874037; PMCID: PMC2384236.
    96. Oh S, Odland R, Wilson SR, Kroeger KM, Liu C, Lowenstein PR, Castro MG, Hall WA, Ohlfest JR. Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg. 2007 Sep; 107(3):568-77. PMID: 17886557; PMCID: PMC2615393.
    97. Oh S, Pluhar GE, McNeil EA, Kroeger KM, Liu C, Castro MG, Lowenstein PR, Freese A, Ohlfest JR. Efficacy of nonviral gene transfer in the canine brain. J Neurosurg. 2007 Jul; 107(1):136-44. PMID: 17639883; PMCID: PMC2384235.
    98. Candolfi M, Pluhar GE, Kroeger K, Puntel M, Curtin J, Barcia C, Muhammad AK, Xiong W, Liu C, Mondkar S, Kuoy W, Kang T, McNeil EA, Freese AB, Ohlfest JR, Moore P, Palmer D, Ng P, Young JD, Lowenstein PR, Castro MG. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol. 2007 Jul; 9(3):245-58. PMID: 17522335; PMCID: PMC1907414.
    99. Candolfi M, Kroeger KM, Pluhar GE, Bergeron J, Puntel M, Curtin JF, McNiel EA, Freese AB, Ohlfest JR, Moore P, Lowenstein PR, Castro MG. Adenoviral-mediated gene transfer into the canine brain in vivo. Neurosurgery. 2007 Jan; 60(1):167-77; discussion 178. PMID: 17228266; PMCID: PMC2095776.
    100. Barcia C, Gerdes C, Xiong WD, Thomas CE, Liu C, Kroeger KM, Castro MG, Lowenstein PR. Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. Neuron Glia Biol. 2006 Nov; 2(4):309-22. PMID: 18084640; PMCID: PMC2139984.
    101. Barcia C, Thomas CE, Curtin JF, King GD, Wawrowsky K, Candolfi M, Xiong WD, Liu C, Kroeger K, Boyer O, Kupiec-Weglinski J, Klatzmann D, Castro MG, Lowenstein PR. In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. J Exp Med. 2006 Sep 04; 203(9):2095-107. PMID: 16923851; PMCID: PMC1997281.
    102. Candolfi M, Curtin JF, Xiong WD, Kroeger KM, Liu C, Rentsendorj A, Agadjanian H, Medina-Kauwe L, Palmer D, Ng P, Lowenstein PR, Castro MG. Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol Ther. 2006 Sep; 14(3):371-81. PMID: 16798098; PMCID: PMC1629029.
    103. Curtin JF, King GD, Barcia C, Liu C, Hubert FX, Guillonneau C, Josien R, Anegon I, Lowenstein PR, Castro MG. Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol. 2006 Mar 15; 176(6):3566-77. PMID: 16517725; PMCID: PMC1592227.
    104. Zirger JM, Liu C, Barcia C, Castro MG, Lowenstein PR. Immune regulation of transgene expression in the brain: B cells regulate an early phase of elimination of transgene expression from adenoviral vectors. Viral Immunol. 2006; 19(3):508-17. PMID: 16987068; PMCID: PMC1847585.
    105. Xiong W, Goverdhana S, Sciascia SA, Candolfi M, Zirger JM, Barcia C, Curtin JF, King GD, Jaita G, Liu C, Kroeger K, Agadjanian H, Medina-Kauwe L, Palmer D, Ng P, Lowenstein PR, Castro MG. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol. 2006 Jan; 80(1):27-37. PMID: 16352528; PMCID: PMC1317549.
    106. Jacobs AH, Winkler A, Castro MG, Lowenstein P. Human gene therapy and imaging in neurological diseases. Eur J Nucl Med Mol Imaging. 2005 Dec; 32 Suppl 2:S358-83. PMID: 16328505; PMCID: PMC2902257.
    107. Seilicovich A, Pisera D, Sciascia SA, Candolfi M, Puntel M, Xiong W, Jaita G, Castro MG. Gene therapy for pituitary tumors. Curr Gene Ther. 2005 Dec; 5(6):559-72. PMID: 16457646.
      View in: PubMed
    108. King GD, Curtin JF, Candolfi M, Kroeger K, Lowenstein PR, Castro MG. Gene therapy and targeted toxins for glioma. Curr Gene Ther. 2005 Dec; 5(6):535-57. PMID: 16457645.
      View in: PubMed
    109. Iannacone M, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR, Chisari FV, Ruggeri ZM, Guidotti LG. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med. 2005 Nov; 11(11):1167-9. PMID: 16258538; PMCID: PMC2908083.
    110. Ali S, King GD, Curtin JF, Candolfi M, Xiong W, Liu C, Puntel M, Cheng Q, Prieto J, Ribas A, Kupiec-Weglinski J, van Rooijen N, Lassmann H, Lowenstein PR, Castro MG. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res. 2005 Aug 15; 65(16):7194-204. PMID: 16103070; PMCID: PMC1242178.
    111. Abordo-Adesida E, Follenzi A, Barcia C, Sciascia S, Castro MG, Naldini L, Lowenstein PR. Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum Gene Ther. 2005 Jun; 16(6):741-51. PMID: 15960605; PMCID: PMC2676203.
    112. Curtin JF, King GD, Candolfi M, Greeno RB, Kroeger KM, Lowenstein PR, Castro MG. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem. 2005; 5(12):1151-70. PMID: 16248789.
      View in: PubMed
    113. Ali S, Curtin JF, Zirger JM, Xiong W, King GD, Barcia C, Liu C, Puntel M, Goverdhana S, Lowenstein PR, Castro MG. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther. 2004 Dec; 10(6):1071-84. PMID: 15564139; PMCID: PMC1440590.
    114. Biglari A, Bataille D, Naumann U, Weller M, Zirger J, Castro MG, Lowenstein PR. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther. 2004 Nov; 11(11):721-32. PMID: 15475879; PMCID: PMC2902255.
    115. Dorigo O, Gil JS, Gallaher SD, Tan BT, Castro MG, Lowenstein PR, Calos MP, Berk AJ. Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J Virol. 2004 Jun; 78(12):6556-66. PMID: 15163748.
      View in: PubMed
    116. Lowenstein PR, Castro MG. Recent advances in the pharmacology of neurological gene therapy. Curr Opin Pharmacol. 2004 Feb; 4(1):91-7. PMID: 15018845; PMCID: PMC2902249.
    117. Ke B, Shen XD, Gao F, Busuttil RW, Löwenstein PR, Castro MG, Kupiec-Weglinski JW. Gene therapy for liver transplantation using adenoviral vectors: CD40-CD154 blockade by gene transfer of CD40Ig protects rat livers from cold ischemia and reperfusion injury. Mol Ther. 2004 Jan; 9(1):38-45. PMID: 14741776; PMCID: PMC2913595.
    118. Kingston PA, Sinha S, Appleby CE, David A, Verakis T, Castro MG, Lowenstein PR, Heagerty AM. Adenovirus-mediated gene transfer of transforming growth factor-beta3, but not transforming growth factor-beta1, inhibits constrictive remodeling and reduces luminal loss after coronary angioplasty. Circulation. 2003 Dec 02; 108(22):2819-25. PMID: 14638551.
      View in: PubMed
    119. Stone D, Xiong W, Williams JC, David A, Lowenstein PR, Castro MG. Adenovirus expression of IL-1 and NF-kappaB inhibitors does not inhibit acute adenoviral-induced brain inflammation, but delays immune system-mediated elimination of transgene expression. Mol Ther. 2003 Sep; 8(3):400-11. PMID: 12946313; PMCID: PMC2913593.
    120. Lowenstein PR, Suwelack D, Hu J, Yuan X, Jimenez-Dalmaroni M, Goverdhana S, Castro MG. Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders. Int Rev Neurobiol. 2003; 55:3-64. PMID: 12968530; PMCID: PMC2902245.
    121. Hurtado-Lorenzo A, David A, Thomas C, Castro MG, Lowenstein PR. Use of recombinant adenovirus for gene transfer into the rat brain. Evaluation of gene transfer efficiency, toxicity, and inflammatory and immune reactions. Methods Mol Med. 2003; 76:113-33. PMID: 12526161.
      View in: PubMed
    122. Guillot C, Ménoret S, Guillonneau C, Braudeau C, Castro MG, Lowenstein P, Anegon I. Active suppression of allogeneic proliferative responses by dendritic cells after induction of long-term allograft survival by CTLA4Ig. Blood. 2003 Apr 15; 101(8):3325-33. PMID: 12515725.
      View in: PubMed
    123. Cowen RL, Williams JC, Emery S, Blakey D, Darling JL, Lowenstein PR, Castro MG. Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane. Cancer Gene Ther. 2002 Nov; 9(11):897-907. PMID: 12386828.
      View in: PubMed
    124. Lowenstein PR, Castro MG. Progress and challenges in viral vector-mediated gene transfer to the brain. Curr Opin Mol Ther. 2002 Aug; 4(4):359-71. PMID: 12222874.
      View in: PubMed
    125. Sarac MS, Windeatt S, Castro MG, Lindberg I. Intrapituitary adenoviral administration of 7B2 can extend life span and reverse endocrinological deficiencies in 7B2 null mice. Endocrinology. 2002 Jun; 143(6):2314-23. PMID: 12021196.
      View in: PubMed
    126. Thomas CE, Edwards P, Wickham TJ, Castro MG, Lowenstein PR. Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types. J Virol. 2002 Apr; 76(7):3452-60. PMID: 11884569; PMCID: PMC136027.
    127. Guillot C, Guillonneau C, Mathieu P, Gerdes CA, Ménoret S, Braudeau C, Tesson L, Renaudin K, Castro MG, Löwenstein PR, Anegon I. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection. J Immunol. 2002 Feb 15; 168(4):1600-9. PMID: 11823487.
      View in: PubMed